Sanofi enters vaccine licensing deal with Novavax, giving beleaguered biotech a lifeline

Taking stock of the drug industry, from the lab to the medicine chest

May 10, 2024 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

NICOLAS MAETERLINCK/BELGA MAG/AFP via Getty Images STAT+ | Sanofi enters vaccine licensing deal with Novavax, giving beleaguered biotech a lifeline Sanofi will help sell Novavax's Covid-19 shot starting next year, and will work on a combined flu-Covid shot. By Andrew Joseph STAT+ | After its last deal fell through, Maze Therapeutics finds new partner for rare disease drug Sanofi had previously moved to license the rare disease therapy, but the deal fell apart under scrutiny from the FTC. By Andrew Joseph STAT+ | CRISPR edits fail to cure HIV patients in early test Excision BioTherapeutics reported Friday that an early trial failed to cure HIV, but plans to try again with a more efficient editing treatment. By Jason Mast

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2024, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser